BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30630717)

  • 1. Shape-based virtual screen for the discovery of novel CDK8 inhibitor chemotypes.
    He LJ; Zhu YB; Fan QZ; Miao DD; Zhang SP; Liu XP; Zhang C
    Bioorg Med Chem Lett; 2019 Feb; 29(4):549-555. PubMed ID: 30630717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel CDK8 inhibitors using multiple crystal structures in docking-based virtual screening.
    Wang T; Yang Z; Zhang Y; Yan W; Wang F; He L; Zhou Y; Chen L
    Eur J Med Chem; 2017 Mar; 129():275-286. PubMed ID: 28231524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening.
    Czodrowski P; Mallinger A; Wienke D; Esdar C; Pöschke O; Busch M; Rohdich F; Eccles SA; Ortiz-Ruiz MJ; Schneider R; Raynaud FI; Clarke PA; Musil D; Schwarz D; Dale T; Urbahns K; Blagg J; Schiemann K
    J Med Chem; 2016 Oct; 59(20):9337-9349. PubMed ID: 27490956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wogonin induced G1 cell cycle arrest by regulating Wnt/β-catenin signaling pathway and inactivating CDK8 in human colorectal cancer carcinoma cells.
    He L; Lu N; Dai Q; Zhao Y; Zhao L; Wang H; Li Z; You Q; Guo Q
    Toxicology; 2013 Oct; 312():36-47. PubMed ID: 23907061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of 3, 4-disubstituted pyridine derivatives as novel CDK8 inhibitors.
    Zhang H; Jing L; Liu M; Goto M; Lai F; Liu X; Sheng L; Yang Y; Yang Y; Li Y; Chen X; Lee KH; Xiao Z
    Eur J Med Chem; 2021 Nov; 223():113634. PubMed ID: 34147745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore.
    Schiemann K; Mallinger A; Wienke D; Esdar C; Poeschke O; Busch M; Rohdich F; Eccles SA; Schneider R; Raynaud FI; Czodrowski P; Musil D; Schwarz D; Urbahns K; Blagg J
    Bioorg Med Chem Lett; 2016 Mar; 26(5):1443-51. PubMed ID: 26852363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition.
    Chen M; Li J; Liang J; Thompson ZS; Kathrein K; Broude EV; Roninson IB
    Cells; 2019 Nov; 8(11):. PubMed ID: 31717492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
    Yu M; Teo T; Yang Y; Li M; Long Y; Philip S; Noll B; Heinemann GK; Diab S; Eldi P; Mekonnen L; Anshabo AT; Rahaman MH; Milne R; Hayball JD; Wang S
    Eur J Med Chem; 2021 Mar; 214():113248. PubMed ID: 33571827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation.
    Yu M; Long Y; Yang Y; Li M; Teo T; Noll B; Philip S; Wang S
    Eur J Med Chem; 2021 Jun; 218():113391. PubMed ID: 33823391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential.
    Fujimoto J; Hirayama T; Hirata Y; Hikichi Y; Murai S; Hasegawa M; Hasegawa Y; Yonemori K; Hata A; Aoyama K; Cary DR
    Bioorg Med Chem; 2017 Jun; 25(12):3018-3033. PubMed ID: 28392276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance.
    Hofmann MH; Mani R; Engelhardt H; Impagnatiello MA; Carotta S; Kerenyi M; Lorenzo-Herrero S; Böttcher J; Scharn D; Arnhof H; Zoephel A; Schnitzer R; Gerstberger T; Sanderson MP; Rajgolikar G; Goswami S; Vasu S; Ettmayer P; Gonzalez S; Pearson M; McConnell DB; Kraut N; Muthusamy N; Moll J
    Mol Cancer Ther; 2020 Apr; 19(4):1018-1030. PubMed ID: 32024684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding patterns and structure-activity relationship of CDK8 inhibitors.
    Ma D; Chen X; Shen XB; Sheng LQ; Liu XH
    Bioorg Chem; 2020 Mar; 96():103624. PubMed ID: 32078847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New CDK8 inhibitors as potential anti-leukemic agents - Design, synthesis and biological evaluation.
    Solum E; Hansen TV; Aesoy R; Herfindal L
    Bioorg Med Chem; 2020 May; 28(10):115461. PubMed ID: 32245563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Search of Novel CDK8 Inhibitors by Virtual Screening.
    Kumarasiri M; Teo T; Yu M; Philip S; Basnet SK; Albrecht H; Sykes MJ; Wang P; Wang S
    J Chem Inf Model; 2017 Mar; 57(3):413-416. PubMed ID: 28191946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains.
    Rzymski T; Mikula M; Żyłkiewicz E; Dreas A; Wiklik K; Gołas A; Wójcik K; Masiejczyk M; Wróbel A; Dolata I; Kitlińska A; Statkiewicz M; Kuklinska U; Goryca K; Sapała Ł; Grochowska A; Cabaj A; Szajewska-Skuta M; Gabor-Worwa E; Kucwaj K; Białas A; Radzimierski A; Combik M; Woyciechowski J; Mikulski M; Windak R; Ostrowski J; Brzózka K
    Oncotarget; 2017 May; 8(20):33779-33795. PubMed ID: 28422713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angel or Devil ? - CDK8 as the new drug target.
    Wu D; Zhang Z; Chen X; Yan Y; Liu X
    Eur J Med Chem; 2021 Mar; 213():113043. PubMed ID: 33257171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors.
    Xi M; Chen T; Wu C; Gao X; Wu Y; Luo X; Du K; Yu L; Cai T; Shen R; Sun H
    Eur J Med Chem; 2019 Feb; 164():77-91. PubMed ID: 30594029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a Novel and Potent Cyclin-Dependent Kinase 8/19 (CDK8/19) Inhibitor for the Treatment of Cancer.
    Xu J; Qi H; Wang Z; Wang L; Steurer B; Cai X; Liu J; Aliper A; Zhang M; Ren F; Zhavoronkov A; Ding X
    J Med Chem; 2024 May; 67(10):8161-8171. PubMed ID: 38690856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?
    Philip S; Kumarasiri M; Teo T; Yu M; Wang S
    J Med Chem; 2018 Jun; 61(12):5073-5092. PubMed ID: 29266937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of potent and selective CDK8 inhibitors through FBDD approach.
    Han X; Jiang M; Zhou C; Zhou Z; Xu Z; Wang L; Mayweg AV; Niu R; Jin TG; Yang S
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4488-4492. PubMed ID: 28802632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.